In this article, we will list the 5 Large Cap Stocks Under $30 With Huge Upside Potential. Please visit 15 Large Cap Stocks Under $30 With Huge Upside Potential if you’d like to see an extended list and how we came up with the list of best large-cap stocks.

5. Rocket Companies Inc. (NYSE:RKT)

Rocket Companies Inc. (NYSE:RKT) is one of the 15 large cap stocks under $30 with huge upside potential.

On March 9, Bank of America Securities marginally reduced its price target on Rocket Companies Inc. (NYSE:RKT) from $24 to $23. The firm reiterated its Buy rating on the stock, which still offers more than 61% upside at the prevailing level.

The revision comes at the back of an uncertain macroeconomic forecast. To account for such an outlook, along with lower valuation multiples, the firm is modifying price estimates for several consumer finance stocks.

Back on February 27, Wells Fargo maintained an Equal Weight rating on Rocket Companies Inc. (NYSE:RKT). The firm increased its price target on the stock from $17 to $19, leading to an adjusted upside of more than 33%.

Wells Fargo noted a positive tone on first-quarter volumes and expects gain-on-sale margins to remain relatively steady. It also highlighted that the company is ahead of pace on synergies from its Mr. Cooper and Redfin acquisitions, while its Compass strategic partnership should help drive higher origination volumes.

Rocket Companies Inc. (NYSE:RKT) operates as a fintech company that delivers various innovative solutions related to real estate, personal finance, and mortgages. Some of its offerings include digital real estate brokerage, home search, appraisals, settlements, subscription cancellation, and credit score improvement.

4. Tencent Music Entertainment Group (NYSE:TME)

Tencent Music Entertainment Group (NYSE:TME) is one of the 15 large cap stocks under $30 with huge upside potential.

On March 18, Wei Fang from Mizuho reduced the firm’s price target on Tencent Music Entertainment Group (NYSE:TME) from $28 to $23. The analyst maintained his Outperform rating on the stock, which still yields almost 131% potential upside even after the revision.

The move follows the company’s fourth-quarter earnings report, in which Fang highlighted uncertainties around competition and AI. He also noted the company faces a balancing act between near-term performance metrics and long-term strategic execution, which weighed on its outlook.

On March 18, UBS downgraded its rating on Tencent Music Entertainment Group (NYSE:TME) from Buy to Neutral. The firm also cut down its target price for the stock, from $26 to $13.

Despite a fourth-quarter sales boost, the firm is adopting a more cautious near-term growth forecast due to growing competitive worries and AI disruption threats. Tencent Music’s capacity to increase basic subscribers and ARPPU is constrained by the ongoing rapid user growth on up-and-coming platforms like Soda Music, and the emergence of AI-generated music raises additional concerns.

Tencent Music Entertainment Group (NYSE:TME) is an entertainment provider that offers online music, streaming, and virtual karaoke services. The company runs online music platforms that allow members to discover and share music, talk shows, audiobooks, podcasts, and other audio content.

3. Figma Inc. (NYSE:FIG)

Figma Inc. (NYSE:FIG) is one of the 15 large cap stocks under $30 with huge upside potential.

On February 19, Rishi Jaluria from RBC Capital reduced the price target on Figma Inc. (NYSE:FIG) from $38 to $31, resulting in an adjusted upside of almost 34% at the current level. The analyst maintained a Sector Perform rating on the stock.

Jaluria stated that although the company had a strong fourth-quarter earnings beat, it would prefer to wait for a better entry price before becoming more bullish. Figma’s excellent gross margin profile, solid position across design and related processes, and growing monetisation possibilities from AI-native products like Dev Mode and Figma Make, all support the company’s recent trading level.

On February 19, Goldman Sachs reduced the firm’s price target on Figma Inc. (NYSE:FIG) from $40 to $35, which still yields an upside potential of almost 51% despite the downward revision. The firm maintained a Neutral rating on the stock.

Goldman Sachs noted that the key debate around the stock has been the defensibility of its core platform in an AI-driven environment, along with potential seat compression across product development teams, which continues to weigh on investor sentiment.

Figma Inc. (NYSE:FIG) operates a browser-based platform that helps teams build products through UI/UX design. It covers multiple stages of product development, including idea generation, prototyping, and design systems. It also offers various other tools such as Dev Mode, FigJam, Figma Slides, Figma Buzz, Figma Draw, and more.

2. Blue Owl Capital Inc. (NYSE:OWL)

Blue Owl Capital Inc. (NYSE:OWL) is one of the 15 large cap stocks under $30 with huge upside potential.

On March 17, Blue Owl Capital Inc. (NYSE:OWL) triggered the recent collapse of Century Capital Partners after uncovering irregularities in its financial reporting and requesting repayment. The firm’s actions came after Century dismissed a director over financial discrepancies, according to people familiar with the matter and reviewed documents.

Laith Al-Khalaf and Robert Smith from The Financial Times noted that Blue Owl’s intervention effectively pushed Century into administration, highlighting the consequences of governance lapses and financial mismanagement.

On March 17, Citizens reduced its price target on Blue Owl Capital Inc. (NYSE:OWL) from $26 to $23. The firm maintained an Outperform rating on the stock, which still offers an impressive upside potential of 153% despite the revision.

According to the firm, building a downside valuation framework for Blue Owl Capital Inc. (NYSE:OWL) is crucial as investors continue to be reactive and momentum-driven in the face of exceptionally weak technicals and sentiment across the larger private capital space.

The firm points out that even in a bear-case scenario, EPS is still expected to increase by more than 5% in 2026 to roughly 90 cents, offering underlying support despite short-term volatility.

Blue Owl Capital Inc. (NYSE:OWL) is an alternative asset manager that offers capital solutions to mid-market companies. With an emphasis on credit, real assets, and GP strategic capital, it provides private financing, direct lending, opportunistic lending, equity financing, and leasing solutions. It is well-reputed for delivering a differentiated route to private markets and secular growth trends.

1. Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics (NASDAQ:SMMT) is one of the 15 large cap stocks under $30 with huge upside potential.

On March 16, Jefferies downgraded its rating for Summit Therapeutics Inc. (NASDAQ:SMMT) from Buy to Hold. The stock was also subject to a substantial target price revision by the firm, from $42 to $15. The firm lists four significant catalysts for Summit in 2026, each of which carries some risk.

Jefferies also noted that, given the ambiguous translation from China to the rest of the world, a clean win is not an easy call for the HARMONi-6 reading. Although Summit Therapeutics Inc. (NASDAQ:SMMT) is the early mover and PD-1/VEGF appears to be a promising class, the firm seeks to find another way to play it.

Back on February 24, Summit Therapeutics (NASDAQ:SMMT) reported its fourth-quarter adjusted EPS of (14c), above the consensus of (1c), reflecting solid operational performance. The company provided updates on its global Phase III HARMONi-3 clinical trial, highlighting progress in both the squamous and non-squamous cohorts.

Screening for the squamous cohort has been completed during the first quarter of 2026, while enrollment for the non-squamous cohort is expected to finish in the second half of the year. Interim analyses for PFS and OS are planned at pre-specified milestones to ensure robust data assessment.

Summit Therapeutics (NASDAQ:SMMT) is a clinical-stage biopharma company that develops and commercializes medical oncology therapies. It is focused on developing ivonescimab, a bispecific antibody that combines blockade of PD-1 and anti-angiogenesis in a single molecule. It is also running Phase III clinical trials for the treatment of non-small lung cancer.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.